# Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and Adolescents

> **NCT07660198** · PHASE3 · RECRUITING · sponsor: **Pfizer** · enrollment: 1200 (estimated)

## Conditions studied

- Pneumococcal Disease

## Interventions

- **BIOLOGICAL:** PG4
- **BIOLOGICAL:** 20-valent pneumococcal conjugate vaccine (20vPnC)

## Key facts

- **NCT ID:** NCT07660198
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-15
- **Primary completion:** 2027-12-02
- **Final completion:** 2027-12-02
- **Target enrollment:** 1200 (ESTIMATED)
- **Last updated:** 2026-08-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07660198

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07660198, "Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and Adolescents". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07660198. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*